PLCG2 promotes hepatocyte proliferation in vitro via NF-κB and ERK pathway by targeting bcl2 , myc and ccnd1
Source abstract
Abstract
Phospholipase Cγ2 (PLCG2) has been implicated in the regulation of cell proliferation, transformation, and tumor growth. In this study, we investigate the mechanism of PLCG2 action using a short interference RNA (siRNA) method. The effects of PLCG2 on rat liver BRL-3A cells treated siRNA were studied by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT assay), bromodeoxyuridine (BrdU) labelling assay, flow cytometry method (FCM), quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. The results showed when PLCG2 was reduced, cell vitality and proliferation rate were significantly decreased (p < .05 vs. control). FCM analysis showed that the number of cell division phase (G2 + M) was declined (p < .05 vs. control). RT-PCR and western blot revealed that the expression of signalling related genes NF-κB, FOS, JUN and ELK, target genes BCL2, CCNB1 and CCND1 were remarkably down-regulated in cells treated with PLCG2 siRNAs. Based on these results, we conclude PLCG2 plays an important role in rat liver cell proliferation via ERK and NF-κB pathway by regulating the expression of BCl2, MYC and CCND1.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: NF-κB Signaling Pathways · Cancer-related Molecular Pathways · Cytokine Signaling Pathways and Interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University
Department of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University
References (44)
Show source-provided references
1. Katan M. The control of inositol lipid hydrolysis. Cancer Surv. 1995;27:199–211.
2. 10.1042/bj288000110.1042/bj2880001 ↗
3. 10.1016/0955-0674(95)80026-310.1016/0955-0674(95)80026-3 ↗
4. 10.1074/jbc.272.24.1504510.1074/jbc.272.24.15045 ↗
5. 10.1016/S0969-2126(96)00146-310.1016/S0969-2126(96)00146-3 ↗
6. 10.1006/jmbi.1997.149010.1006/jmbi.1997.1490 ↗
7. 10.1016/S0005-2760(97)00158-610.1016/S0005-2760(97)00158-6 ↗
8. 10.1007/BF0221102110.1007/BF02211021 ↗
9. 10.1016/S0014-5793(97)00415-810.1016/S0014-5793(97)00415-8 ↗
10. 10.1016/S0005-2760(98)00125-810.1016/S0005-2760(98)00125-8 ↗
11. 10.1242/jcs.114.24.455710.1242/jcs.114.24.4557 ↗
12. 10.1038/7193610.1038/71936 ↗
13. 10.1101/pdb.prot09550510.1101/pdb.prot095505 ↗
14. 10.1007/s10735-018-9761-810.1007/s10735-018-9761-8 ↗
15. Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. Meth Mol Biol. 2004;281:301–311.
16. 10.1007/978-1-4939-2742-5_910.1007/978-1-4939-2742-5_9 ↗
17. 10.1016/j.hep.2003.09.01910.1016/j.hep.2003.09.019 ↗
18. 10.1172/JCI48310.1172/JCI483 ↗
19. 10.1172/JCI021529510.1172/JCI0215295 ↗
20. 10.1155/2010/59810910.1155/2010/598109 ↗
21. 10.3748/wjg.v10.i1.2210.3748/wjg.v10.i1.22 ↗
22. 10.1186/1742-2094-7-8810.1186/1742-2094-7-88 ↗
23. 10.1038/sj.onc.120613210.1038/sj.onc.1206132 ↗
24. 10.1046/j.1471-4159.2000.0750683.x10.1046/j.1471-4159.2000.0750683.x ↗
25. 10.1002/ptr.317110.1002/ptr.3171 ↗
26. Yang GF, Deng CS, Xiong YY, et al. Expression of NFkappaB p65 and its target genes in gastric cancer and precancerous lesions. Zhonghua zhong liu za zhi [Chinese Journal of Oncology]. 2004;26(9):551–553.
27. 10.1016/0955-0674(94)90035-310.1016/0955-0674(94)90035-3 ↗
28. 10.1016/S0065-230X(08)60765-410.1016/S0065-230X(08)60765-4 ↗
29. 10.1016/S0955-0674(97)80061-010.1016/S0955-0674(97)80061-0 ↗
30. 10.2337/diabetes.49.12.216010.2337/diabetes.49.12.2160 ↗
31. 10.1074/jbc.M30377120010.1074/jbc.M303771200 ↗
32. 10.1152/jappl.2001.91.3.141210.1152/jappl.2001.91.3.1412 ↗
33. 10.1016/j.neuint.2003.07.00210.1016/j.neuint.2003.07.002 ↗
34. 10.1074/jbc.270.40.2358910.1074/jbc.270.40.23589 ↗
35. 10.1016/S0014-5793(98)01549-X10.1016/S0014-5793(98)01549-X ↗
36. Nelsen CJ, Rickheim DG, Timchenko NA, et al. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res. 2001;61(23):8564–8568.
37. 10.1053/jhep.2002.3399610.1053/jhep.2002.33996 ↗
38. 10.1074/jbc.272.47.2946810.1074/jbc.272.47.29468 ↗
39. 10.1146/annurev.cb.10.110194.00220110.1146/annurev.cb.10.110194.002201 ↗
40. Herber B, Truss M, Beato M, et al. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene. 1994;9(4):1295–1304.
41. 10.1128/MCB.18.6.321210.1128/MCB.18.6.3212 ↗
42. 10.1128/MCB.16.12.691710.1128/MCB.16.12.6917 ↗
43. 10.1126/science.274.5293.167210.1126/science.274.5293.1672 ↗
44. 10.1016/0092-8674(95)90385-210.1016/0092-8674(95)90385-2 ↗